Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan for persistent retinal pigment epithelial detachment
ChiCTR2600132082Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telmisartan in pigment epithelium detachment (PED), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Proportion of patients with at least 50% reduction or complete resolution of PED cross-sectional area at 3 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
telmisartan
03
Conditions
pigment epithelium detachment (PED)
Beyond the preview
Go deeper on ChiCTR2600132082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132082.